Use of antagonists in ovarian stimulation protocols

Reproductive BioMedicine Online

Volumn 10, Issue 3, 2005, Pages 330-338

  Dal Prato, Luca ^a   Borini, Andrea ^a  

^a Tecnobios Procreazione   (Italy)

Author keywords

GnRH agonists; GnRH antagonists; IVF; Ovarian stimulation

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; ESTRADIOL; GANIRELIX; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG USE; EMBRYO TRANSFER; FERTILIZATION IN VITRO; GONADOTROPIN RELEASE; HORMONE SYNTHESIS; HUMAN; HYPOPHYSIS CELL; LUTEINIZING HORMONE RELEASE; META ANALYSIS; OVARY DISEASE; OVARY FOLLICLE; OVULATION INDUCTION; PREGNANCY RATE; SINGLE DRUG DOSE;

EID: 14944342733     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61792-0     Document Type: Article

References (80)

1. Aboulghar MA, Mansour RT, Serour GI et al. 2004 Increasing the dose of human menopausal gonadotrophins on day of GnRH antagonist administration: randomized controlled trial. Reproductive BioMedicine Online 8, 524-527.
2. Akman MA, Erden HF, Tosun SB et al. 2001 Comparison of agonistic, flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Human Reproduction 16, 868-870.
3. Albano C, Felberbaum RE, Smitz J et al. 2000 Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Human Reproduction 15, 526-531.
4. Albano C, Smitz J, Tournaye H et al. 1999 Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles. Human Reproduction 14, 1426-1430.
5. Albano C, Grimbizis G, Smitz J et al. 1998 The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist cetrorelix. Fertility and Sterility 70, 357-359.
6. Albano C, Smitz J, Camus M et al. 1997 Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertility and Sterility 67, 917-922.
7. Al-Inany H, Aboulghar M 2004 Gonadotrophin-releasing hormone antagonists for assisted conception (Cochrane Review). The Cochrane Library, Issue 1, CD001750.
8. Asimakopoulos B, Nikolettos N, Al-Hasani S 2002 Outcome of cryopreserved pronuclear oocytes obtained after ovarian stimulation with either HMG or recFSH and the GnRH-antagonist cetrorelix. Reproductive BioMedicine Online 5, 52-56.
9. Ben-Rafael Z, Lipitz S, Bider D et al. 1991 Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels. Fertility and Sterility 55, 272-275.
10. Borm G, Mannaerts B 2000 Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Human Reproduction 15, 1490-1498.
11. Caspi E, Ron-El R, Golan A et al. 1989 Results of in vitro fertilization and embryo transfer by combined long-acting gonadotropin-releasing hormone analog D-Trp-6-luteinizing hormone-releasing hormone and gonadotropins. Fertility and Sterility 51, 95-99.
12. Cedrin-Durnerin I, Grange-Dujardin D, Laffy A et al. 2004 Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Human Reproduction 19, 1979-1984.
13. Coccia ME, Comparetto C, Bracco GL et al. 2004 GnRH antagonists. European Journal of Obstetrics and Gynecology and Reproductive Biology 115, S44-56.
14. Conn PM 1986 The molecular basis of gonadotropin-releasing hormone action. Endocrine Reviews 7, 3-10.
15. Craft I, Gorgy A, Hill J et al. 1999 Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols? Human Reproduction. 14 2959-2962.
16. Dal Prato L, Borini A, Coticchio G et al. 2004 Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study. Human Reproduction 19, 2200-2205.
17. Dal Prato L, Borini A, Trevisi MR et al. 2001 Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study. Human Reproduction 16, 1409-1414.
18. Diedrich K, Diedrich C, Santos E et al. 1994 Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation. Human Reproduction 9, 788-791.
19. Engel JB, Ludwig M, Junge K et al. 2003a No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multiple-dose protocols. Reproductive BioMedicine Online 6, 482-487.
20. Engel JB, Olivennes F, Fanchin R et al. 2003b Single dose application of cetrorelix in combination with clomiphene for friendly IVF: results of a feasibility study. Reproductive BioMedicine Online 6, 444-447.
21. Escudero E, Bosch E, Crespo J et al. 2004 Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients. Fertility and Sterility 81, 562-566.
22. European and Middle East Orgalutran Study Group 2001 Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 16, 644-651.
23. Fasouliotis SJ, Laufer N, Sabbagh-Ehrlich S et al. 2003 Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF. Journal of Assisted Reproduction and Genetics 20, 455-460.
24. Fauser BC, de Jong D, Olivennes F et al. 2002 Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. Journal of Clinical Endocrinology and Metabolism 87, 709-715.
25. Felberbaum RE, Reissmann T, Kupker W et al. 1995 Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (cetrorelix) in women with tubal infertility. European Journal of Obstetrics and Gynecology and Reproductive Biology 61 151-155.
26. Felberbaum RE, Albano C, Ludwig M et al. 2000 Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Human Reproduction 15, 1015-1020.
27. Ferrier A, Rasweiler JJT, Bedford JM et al. 1990 Evaluation of leuprolide acetate and gonadotropins versus clomiphene citrate and gonadotropins for in vitro fertilization or gamete intrafallopian transfer. Fertility and Sterility 54, 90-95.
28. Fluker M, Grifo J, Leader A et al. 2001 Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 75 38-45.
29. Ganirelix Dose-Finding Study Group 1998 A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirefix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Human Reproduction. 13, 3023-3031.
30. Hahn DW, McGuire JL, Vale WW et al. 1985 Reproductive/endocrine and anaphylactoid properties of an LHRH-antagonist, ORF 18260 [Ac-DNAL1(2), 4FDPhe2, D-Trp3 ,D-Arg6]-GnRH. Life Sciences 37, 505-514.
31. Hernandez ER 2000 Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Human Reproduction 15, 1211-1216.
32. Hughes EG, Fedorkow DM, Daya S et al. 1992 The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertility and Sterility 58, 888-896.
33. Itskovitz J, Boldes R, Levron J et al. 1991 Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertility and Sterility 56, 213-220.
34. Itskovitz-Eldor J, Kol S, Mannaerts B 2000 Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Human Reproduction 15, 1965-1968.
35. Kol S 2004 Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertility and Sterility 81, 1-5.
36. Kol S, Lightman A, Hillensjo T et al. 1999 High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Human Reproduction 14, 2242-2244.
37. Kolibianakis E, Zikopoulos K, Camus M et al. 2004 Modified natural cycle for IVF does not offer a realistic chance of parenthood in poor responders with high day 3 FSH levels, as a last resort prior to oocyte donation. Human Reproduction 19, 2545-2549.
38. Kolibianakis EM, Albano C, Kahn J et al. 2003 Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertility and Sterility 79, 873-880.
39. Lin Y, Kahn JA, Hillensjo T 1999 Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist? Human Reproduction 14, 885-888.
40. Liu H, Lai Y, Davis O et al. 1992 Improved pregnancy outcome with gonadotropin releasing hormone agonist stimulation is due to the improvement in oocyte quantity rather than quality. Journal of Assisted Reproduction and. Genetics 9, 338-342.
41. Ludwig M, Katalinic A, Banz C et al. 2002 Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study. Human Reproduction 17, 2842-2845.
42. Ludwig M, Katalinic A, Diedrich K 2001 Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Archives of Gynecology and Obstetrics 265, 175-182.
43. Ludwig M, Felberbaum RE, Devroey P et al. 2000 Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics 264, 29-32.
44. Mannaerts B, Gordon K 2000 Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor. Human Reproduction 15, 1882-1883.
45. Mansour R, Aboulghar M, Serour GI et al. 2003a The use of clomiphene citrate/human menopausal gonadotrophins in conjunction with GnRH antagonist in an IVF/ICSI program is not a cost effective protocol. Acta Obstetricia et Gynecologica Scandinavica 82, 48-52.
46. Mansour RT, Aboulghar MA, Serour GI et al. 2003b The use of gonadotropin-releasing hormone antagonist in a flexible protocol: a pilot study. American Journal of Obstetetrics and Gynecology 189, 444-446.
47. Nevo O, Eldar-Geva T, Kol S et al. 2003 Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Fertility and Sterility 79, 1123-1128.
48. Nikolettos N, Asimakopoulos B, Simopoulou M et al. 2004 Gonadotropin releasing hormone antagonists and cryopreservation outcome: a review. Archives of Gynecology and Obstetrics 270, 69-73.
49. Nikolettos N, Al-Hasani S, Felberbaum R et al. 2001 Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. European Journal of Obstetrics and Gynecology and Reproductive Biology 97, 202-207.
50. Oberye JJ, Mannaerts BM, Huisman JA et al. 1999a Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertility and Sterility 72, 1006-1012.
51. Oberye JJ, Mannaerts BM, Kleijn HJ et al. 1999b Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertility and Sterility 72, 1001-1005.
52. Obruca A, Fischl F, Huber J 2000 GnRH Antagonisten bei der kontrollierten ovariellen Hyperstimulation im Rahmen der IVF-Optimierung der Planbarkeit. Journal of Fertility and Reproduction 4, 37.
53. Olivennes F, Fanchin R, Bouchard P et al. 1994 The single or dual administration of the gonadotropin-releasing hormone antagonist cetrorelix in an in vitro fertilization-embryo transfer program. Fertility and Sterility 62, 468-476.
54. Olivennes F, Fanchin R, Bouchard P et al. 1995 Scheduled administration of a gonadotrophin-releasing hormone antagonist (cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study. Human Reproduction 10, 1382-1386.
55. Olivennes F, Fanchin R, Bouchard P et al. 1996 Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertility and Sterility 66, 151-153.
56. Olivennes F, Alvarez S, Bouchard P et al. 1998 The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Human Reproduction 13, 2411-2414.
57. Olivennes F, Belaisch-Allart J, Emperaire J et al. 1999 The use of HMG versus rec-FSH with the single dose GnRH antagonist (cetrorelix) protocol in IVF-ET: a prospective randomized study. Fertility and Sterility. 72, S114.
58. Olivennes F, Belaisch-Allart J, Emperaire JC et al. 2000 Prospective, randomized, controlled study of in vitro fertilization - embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertility and Sterility 73, 314-320.
59. Olivennes F, Diedrich K, Frydman R et al. 2003 Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb, clinical experiences. Reproductive BioMedicine Online 6, 432-438.
60. Pelinck MJ, Hoek A, Simons AH et al. 2002 Efficacy of natural cycle IVF: a review of the literature. Human Reproduction Update 8, 129-139.
61. Penzias AS 2004 Improving results with assisted reproductive technologies: individualized patient-tailored strategies for ovulation induction. Reproductive BioMedicine Online 9, 43-46.
62. Pritts EA, Atwood AK 2002 Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Human Reproduction 17, 2287-2299.
63. Rabinovici J, Rothman P, Monroe SE et al. 1992 Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 75, 1220-1225.
64. Ragni G, Vegetti W, Baroni E et al. 2001 Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. Human Reproduction 16, 2258-2262.
65. Reissmann T, Felberbaum R, Diedrich K et al. 1995 Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Human Reproduction 10, 1974-1981.
66. Rizk B, Smitz J 1992 Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. Human Reproduction 7, 320-327.
67. Ron-El R, Herman A, Golan A et al. 1989 Follicle cyst formation following long-acting gonadotropin-releasing hormone analog administration. Fertility and Sterility 52, 1063-1066.
68. Rongieres-Bertrand C, Olivennes F, Righini C et al. 1999 Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (cetrorelix): a pilot study with minimal stimulation. Human Reproduction 14, 683-688.
69. Roulier R, Chabert-Orsini V, Sitri MC et al. 2003 Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment. Reproductive BioMedicine Online 7, 185-189.
70. Seelig AS, Al-Hasani S, Katalinic A et al. 2002 Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertility and Sterility 77, 472-475.
71. Shapiro DB 2003 GnRH antagonists in normal-responder patients. Fertility and Sterility 80, S8-15; discussion S32-34.
72. Smith EM, Anthony FW, Gadd SC et al. 1989 Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme. British Medical Journal 298, 1483-1486.
73. Smitz J, Devroey P, Camus M et al. 1988 The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Human Reproduction 3, 585-590.
74. Tavaniotou A, Albano C, Smitz J et al. 2001 Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist cetrorelix. Human Reproduction 16, 663-667.
75. Vlaisavljevic V, Reljic M, Lovrec VG et al. 2003 Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles - a prospective, randomized study. Reproductive BioMedicine Online 7, 301-308.
76. Weghofer A, Margreiter M, Bassim S et al. 2004 Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age. Fertility and Sterility 81, 1002-1006.
77. Westergaard L, Yding Andersen C, Humaidan P et al. 2004 Significant reduction of clinical pregnancy and implantation rates by use of GnRH agonist (Buserelin) as compared to hCG to induce ovulation in FSH/GnRH antagonist treated IVF/ICSI cycles. Human Reproduction 19, i3-i4.
78. Wikland M, Bergh C, Borg K et al. 2001 A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Human Reproduction 16, 1676-1681.
79. Williams SC, Gibbons WE, Muasher SJ et al. 2002 Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist. Fertility and Sterility 78, 1068-1072.
80. Zorn JR, Boyer P, Guichard A 1987 Never on a Sunday: programming for IVF-ET and GIFT [letter]. Lancet 1, 385-386.